Patents by Inventor Mark Kieran

Mark Kieran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR SCREENING PEDIATRIC GLIOMAS AND METHODS OF TREATMENT THEREOF
    Publication number: 20190062846
    Abstract: The present invention provides methods for screening and diagnosing pediatric low-grade glioma (PLGG) based on a correlation between angiocentric glioma and MYB-QKI rearrangement. Specific methods for detecting the rearrangement encompass cytogenetic methods, DNA sequencing, RNA sequencing and antibody-based methods to detect the fusion protein.
    Type: Application
    Filed: January 27, 2017
    Publication date: February 28, 2019
    Inventors: RAMEEN BEROUKHIM, KEITH LIGON, ADAM RESNICK, PRATITI BANDOPADHAYAY, LORI RAMKISSOON, PAYAL JAIN, GUILLAUME BERGTHOLD, JEREMIAH WALA, MARK KIERAN
  • METHODS OF PROMOTING TISSUE GROWTH AND TISSUE REGENERATION
    Publication number: 20120315283
    Abstract: Described herein are methods of using soluble epoxide hydrolase inhibitors to modulate the levels of epoxyeicosatrienoic acids (EETs) in order to increase angiogenesis and promote wound healing and tissue regeneration.
    Type: Application
    Filed: February 1, 2011
    Publication date: December 13, 2012
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Dipak Panigraphy, Mark Kieran
  • Methods for inhibiting vascular permeability
    Publication number: 20050112063
    Abstract: The present invention relates to methods for decreasing or inhibiting disorders associated with vascular hyperpermeability and to methods of screening for compounds that affect permeability, angiogenesis and stabilize tight junctions. In one aspect of the present invention there is provided a method of decreasing or inhibiting vascular hyperpermeability in an individual in need of such treatment. The method includes administering to the individual an effective amount of an antiangiogenic compound selected from the group consisting of endostatin, thrombospondin, angiostatin, tumstatin, arrestin, recombinant EPO and polymer conjugated TNP-470. Other antiangiogenic compounds are disclosed herein.
    Type: Application
    Filed: October 12, 2004
    Publication date: May 26, 2005
    Inventors: Shay Soker, Mark Kieran